EarningsQ1 2026 Earnings Report
DE:CUS1 Q1 2026 EPS Results
Actual EPS-€22.31
Consensus EPS-€5.83
Beat/MissMissed by -€16.48
One Year Ago EPS-€22.31
DE:CUS1 Q1 2026 Revenue Results
Actual Revenue€0.00
Expected Revenue€1.51M
Beat/MissMissed by -€1.51M
YoY Revenue Growth-100.00%
Earnings Announcement Details
QuarterQ1 2026
Date05/12/2026
TimeAfter Close
Conference CallTuesday, May 12, 2026
DE:CUS1 Upcoming Earnings
Curis's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q1 2026 Earnings Call Audio
DE:CUS1 Q1 2026 Earnings Call
0:00 / 0:00
Q1 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress and clear near‑term milestones — notably advancement of a registrational PCNSL study with the potential for accelerated submissions, initiation and early milestones for a CLL proof‑of‑concept study, encouraging early collaborator data in gastroesophageal cancer, and collaborative/regulatory engagement. Offsetting these positives are a sizable increase in reported net loss (driven by warrant fair‑value changes), higher G&A tied to financing, a cash runway that depends in part on a milestone contingent warrant exercise, and expected enrollment variability in ultra‑orphan indications. On balance, the clinical and regulatory momentum and near‑term data/milestone visibility materially outweigh the financial and enrollment risks described.Company Guidance
Progress on TakeAim Lymphoma (PCNSL) Registrational Study
Continued steady progress on the single-arm registrational TakeAim Lymphoma study in relapsed/refractory primary CNS lymphoma (PCNSL) with an ORR endpoint; company expects the study to support accelerated submissions in the U.S. and Europe and anticipates updated combination data with ibrutinib in the first half of 2027. Enrollment is described as 'on track' despite the ultra-orphan patient population.
Initiation and Near-Term Milestones for CLL Proof‑of‑Concept Study
TakeAim CLL combination study (emavusertib + zanubrutinib) planning dosing of the initial 5 patients by mid‑2026 with initial data expected in December (2026); study will evaluate two doses (100 mg and 200 mg) to satisfy Project Optimus requirements and assess potential for deeper responses (CR/MRD‑negative) enabling time‑limited treatment.
Encouraging Early Clinical Data in Gastroesophageal Cancer
Collaborator presented initial poster data at ASCO GI showing results for 16 evaluable patients treated with emavusertib + FOLFOX + anti‑PD‑1 ± Herceptin in first‑line metastatic/unresectable gastroesophageal cancer, reporting a manageable toxicity profile and encouraging preliminary efficacy signals.
Collaborations and Regulatory Engagement
Ongoing collaborations with Aurigene, the NCI, academic KOLs (including Siteman/Washington University), and productive discussions with both FDA and EMA that informed trial design and accelerated pathway expectations.
Operating Expense and R&D Efficiency
Research & development expenses decreased to $6.4 million in Q1 2026 from $8.5 million in Q1 2025, a decline of $2.1 million or ~24.7%, primarily due to lower employee‑related and manufacturing costs.
Cash Position and Contingent Financing That Extends Runway
Cash and cash equivalents of $15.0 million as of March 31, 2026, plus anticipated gross proceeds of up to $20.2 million from exercise of January 2026 PIPE Series B warrants contingent on dosing the fifth CLL patient — company states this should enable planned operations into the second half of 2027.
DE:CUS1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed